Management Strategies for Primary Dysmenorrhea

  • Roger P. Smith


In 1910, Dr. P. Brooke Bland wrote, “Dysmenorrhea should never be regarded as a morbid process, but should always be looked upon as a manifestation of some systemic or local pelvic condition. It is unfortunate that many women are operated upon for dysmenorrhea without the cause first being determined” [1]. In the past, therapies used to treat dysmenorrhea have ranged from the plausible and somewhat effective, to the outlandish and useless. Everything from cauterizing the middle turbinate of the nose [2], exercise programs [3], and presacral sympathectomy [4, 5] to uterine relaxing factor [6], vasodilators [7, 8], tranquilizers [9], and hormones [10, 11] have been recommended to relieve dysmenorrhea. The use of electric current has even been advocated [12], employing an insulated chair, an intravaginal electrode, and a spark gap high-voltage generator. This treatment was to be administered for 20 min daily over a 4-week period. The treatment was reported to have had good effects, possibly do to a low return rate of patients treated in this way.


Pharmacology Non-steroidal anti-inflammatory drug (NSAID) Hormonal treatment Heat therapy Transcutaneous electrical stimulation (TENS) Diet Exercise Complementary and alternative therapy Surgical management 


  1. 1.
    Bland PB. Dysmenorrhea; its significance and treatment. J Med Soc NJ. 1910;6(12):591–4.Google Scholar
  2. 2.
    Mayer E. The intranasal treatment of dysmenorrhea. With a report of ninety-three cases. JAMA. 1914;62(1):6–8.CrossRefGoogle Scholar
  3. 3.
    Miller NF, Berkman SJ. Dysmenorrhea. Amer. J Obstet Gynecol. 1953;65:505–16.CrossRefGoogle Scholar
  4. 4.
    Cotte G. La sympathectomie hypogastrique: A-t-elle sa place dans latherapeutique gynecologique? Presse Med. 1925;33:98–102.Google Scholar
  5. 5.
    Black WT Jr. Use of presacral sympathectomy in the treatment of dysmenorrhea: a second look after twenty-five years. Am J Obstet Gynecol. 1964;89:16–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Hayden GE. Relief of primary dysmenorrhea. Obstet Gynecol. 1960;16:730–3.PubMedGoogle Scholar
  7. 7.
    Schuck F. Pain and pain relief in essential dysmenorrhea. Am J Obstet Gynecol. 1951;62(3):559–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Voulgaris DM. Dysmenorrhea. Treatment with Isoxsuprine. Obstet Gynecol. 1960;15:220–2.Google Scholar
  9. 9.
    Champlin WD, Corbit JP. Chlorpromazine and chlorpromazine combinations in the treatment of dysmenorrhea. Am J Obstet Gynecol. 1957;74(2):419–21.CrossRefGoogle Scholar
  10. 10.
    Filler W. The treatment of dysmenorrhea. With special reference to the primary type. Med Clin North Am. 1951;35:861–70.Google Scholar
  11. 11.
    Menaker JS, Powers KD. Management of primary dysmenorrhea. Obstet Gynecol. 1962;20:66–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Torbett JW. The diagnosis and office treatment of some gynecologic cases. Texas State J Med. 1902;4(9):224–6.Google Scholar
  13. 13.
    Hulbert GT. Electricity vs. tait, or the use of electricity in inflammation as found in gynecology. St. Louis Courier of Medicine. 1888;20(3):193–217. (shown: Figures 1–2, p. 207)Google Scholar
  14. 14.
    Pickles VR. Prostaglandins in the human endometrium. Int J Fertil. 1967;12:335–8.PubMedGoogle Scholar
  15. 15.
    Smith RP, Powell JR. The objective evaluation of dysmenorrhea therapy. Am J Obstet Gynecol. 1980;137:314–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Smith RP, Powell JR. Intrauterine pressure changes during mefenamic acid treatment of primary spasmodic dysmenorrhea. Am J Obstet Gynecol. 1982;143:286–92.PubMedGoogle Scholar
  17. 17.
    Smith RP, Powell JR. Simultaneous objective and subjective evaluation of meclofenamate sodium in the treatment of primary dysmenorrhea. Am J Obstet Gynecol. 1987;157(3):611–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Smith RP. The dynamics of nonsteroidal anti-inflammatory therapy for primary dysmenorrhea. Obstet Gynecol. 1987;70(5):7858.Google Scholar
  19. 19.
    Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;(7):CD001751.Google Scholar
  20. 20.
    Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010;81(3):185–96.PubMedCrossRefGoogle Scholar
  21. 21.
    Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol. 1993;169:1255–65.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang WY, Po ALW. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998;105:780–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Lundström V. Treatment of primary dysmenorrhea with prostaglandin synthetase inhibitors—a promising therapeutic alternative. Acta Obstet Gynecol Scand. 1978;57(5):421–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Dingfelder JR. Primary dysmenorrhea treatment with prostaglandin inhibitors: a review. Am J Obstet Gynecol. 1981;140(8):874–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Gookin KS, Forman ES, Vecchio TJ, Wiser WL, Morrison JC. Comparative efficacy of ibuprofen, indomethacin, and placebo in the treatment of primary dysmenorrhea. South Med J. 1983;76(11):1361–2. 1367PubMedCrossRefGoogle Scholar
  26. 26.
    Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Am J Obstet Gynecol. 1984;148:96–103.PubMedCrossRefGoogle Scholar
  27. 27.
    Rees MC, Cañete-Solér R, López Bernal A, Turnbull AC. Effect of fenamates on prostaglandin E receptor binding. Lancet. 1988;2(8610):541–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Casey FB, Appleby BJ, Buck DC. Selective inhibition of the lipoxygenase metabolic pathway of arachidonic acid by the SRA-A antagonist, FPL 55712. Prostaglandins. 1983;25:1–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Myers RF, Siegel MI. Differential effects of anti-inflammatory drugs on lipoxygenase and cyclooxygenase activities of neutrophils from a reverse passive Arthus reaction. Biochem Biophys Res Commun. 1983;112:586–94.PubMedCrossRefGoogle Scholar
  30. 30.
    Boctor AM, Eickholt M, Pugsley TA. Meclofenamate sodium is an inhibitor of both the 5-Lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986;23:229–38.PubMedCrossRefGoogle Scholar
  31. 31.
    Harel Z. Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies. Expert Opin Pharmacother. 2012;13(15):2157–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med. 1981;70(3):535–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Lindh I, Ellström AA, Milsom I. The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study. Hum Reprod. 2012;27(3):676–82.PubMedCrossRefGoogle Scholar
  34. 34.
    Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev. 2009;(4):CD002120.Google Scholar
  35. 35.
    Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception. 2007;75:420–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Harada T, Momoeda M. Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2016;106(7):1807–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Momoeda M, Kondo M, Elliesen J, Yasuda M, Yamamoto S, Harada T. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. Int J Womens Health. 2017;9:295–305.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Imai A, Matsunami K, Takagi H, Ichigo S. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clin Exp Obstet Gynecol. 2014;41(5):495–8.PubMedGoogle Scholar
  39. 39.
    Gold MA, Johnson LM. Intrauterine devices and adolescents. Curr Opin Obstet Gynecol. 2008;20(5):464–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(Suppl 2):21–8.PubMedGoogle Scholar
  41. 41.
    Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. Contraception. 2009;79:29–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Aydar CK, Coleman BD. Treatment of primary dysmenorrhea: a double blind study. JAMA. 1965;192(11):161–3.CrossRefGoogle Scholar
  43. 43.
    Dmitrovic R, Kunselman AR, Legro RS. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial. Hum Reprod. 2013;28:2958–65.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Aktaş D. Prevalence and factors affecting dysmenorrhea in female university students: effect on general comfort level. Pain Manag Nurs. 2015;16(4):534–43.PubMedCrossRefGoogle Scholar
  45. 45.
    De Sanctis V, Soliman AT, Elsedfy H, Soliman NA, Soliman R, El Kholy M. Dysmenorrhea in adolescents and young adults: a review in different country. Acta Biomed. 2017;87(3):233–46.PubMedGoogle Scholar
  46. 46.
    O’Connell K, Davis AR, Westhoff C. Self-treatment patterns among adolescent girls with dysmenorrhea. J Pediatr Adolesc Gynecol. 2006;19:285–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Vance AR, Hayes SH, Spielholz NI. Microwave diathermy treatment for primary dysmenorrhea. Phys Ther. 1996;76:1003–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Use of continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. 2001;97:343–9.PubMedGoogle Scholar
  49. 49.
    Akin MD, Price W, Rodriguez G Jr, Erasala G, Hurley G, Smith RP. Continuous low-level topical heat wrap therapy compared to acetaminophen for primary dysmenorrhea. J Reprod Med. 2004;49:739–45.PubMedGoogle Scholar
  50. 50.
    Lee B, Hong SH, Kim K, et al. Efficacy of the device combining high-frequency transcutaneous electrical nerve stimulation and thermotherapy for relieving primary dysmenorrhea: a randomized, single-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;194:58–63.PubMedCrossRefGoogle Scholar
  51. 51.
    Lundeberg T, Bondesson L, Lundström V. Relief of primary dysmenorrhea by transcutaneous electrical nerve stimulation. Acta Obstet Gynecol Scand. 1985;64(6):491–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108:428.PubMedCrossRefGoogle Scholar
  53. 53.
    Milsom I, Hedner N, Mannheimer CA. Comparative study of the effect of high-intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patients with primary dysmenorrhea. Am J Obstet Gynecol. 1994;170(1 Pt 1):123–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Smith RP, Heltzel J. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report. J Reprod Med. 1991;36:260–4.PubMedGoogle Scholar
  55. 55.
    Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea (Cochrane review). Cochrane Database Syst Rev. 2002;(1):CD002123.Google Scholar
  56. 56.
    Wang SF, Lee JP, Hwa HL. Effect of transcutaneous electrical nerve stimulation on primary dysmenorrhea. Neuromodulation. 2009;12(4):302–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Kaplan B, Peled Y, Pardo J, et al. Transcutaneous electrical nerve stimulation (TENS) as a relief for dysmenorrhea. Clin Exp Obstet Gynecol. 1994;21(2):87–90.PubMedGoogle Scholar
  58. 58.
    Dawood MY, Ramos J. Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen. Obstet Gynecol. 1990;75(4):656–60.PubMedGoogle Scholar
  59. 59.
    Igwea SE, Tabansi-Ochuogu CS, Abaraogu UO. TENS and heat therapy for pain relief and quality of life improvement in individuals with primary dysmenorrhea: a systematic review. Complement Ther Clin Pract. 2016;24:86–91.PubMedCrossRefGoogle Scholar
  60. 60.
    Proctor ML, Murphy PA, Pattison HM, et al. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2007;(3):CD002248.Google Scholar
  61. 61.
    Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;(3):CD002124.Google Scholar
  62. 62.
    Daily JW, Zhang X, Kim DS, Park S. Efficacy of ginger for alleviating the symptoms of primary dysmenorrhea: A systematic review and meta-analysis of randomized clinical trials. Pain Med. 2015;16(12):2243–55.PubMedCrossRefGoogle Scholar
  63. 63.
    Chen CX, Barrett B, Kwekkeboom KL. Efficacy of oral ginger (Zingiber officinale) for dysmenorrhea: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016;2016:6295737.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG. 2005;112(4):466–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Mehrpooya M, Eshraghi A, Rabiee S, Larki-Harchegani A, Ataei S. Comparison of the effect of fish-oil and calcium supplementation on treatment of primary dysmenorrhea. Rev Recent Clin Trials. 2017;12(3):148–53.PubMedCrossRefGoogle Scholar
  66. 66.
    Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;(3):CD002124.Google Scholar
  67. 67.
    Israel RG, Sutton M, O’Brien KF. Effects of aerobic training on primary dysmenorrhea symptomatology in college females. J Am Coll Heal. 1985;33:241–4.CrossRefGoogle Scholar
  68. 68.
    Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2010;(2):CD004142.Google Scholar
  69. 69.
    Golomb LM, Solidum AA, Warren MP. Primary dysmenorrhea and physical activity. Med Sci Sports Exerc. 1998;30:906–9.PubMedGoogle Scholar
  70. 70.
    Metheny WP, Smith RP. The relationship between exercise, stress, and primary dysmenorrhea. J Behav Med. 1989;12:569–86.PubMedCrossRefGoogle Scholar
  71. 71.
    Rakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: a randomized clinical trial. J Pediatr Adolesc Gynecol. 2011;24:192–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Yang NY, Kim SD. Effects of a yoga program on menstrual cramps and menstrual distress in undergraduate students with primary dysmenorrhea: a single-blind, randomized controlled trial. J Altern Complement Med. 2016;22(9):732–8.PubMedGoogle Scholar
  73. 73.
    Hatcher RA. Counseling couples about coitus during menstrual flow. Contracept Technol Update. 1981;2:167.PubMedGoogle Scholar
  74. 74.
    Juang CM, Yen MS, Twu NF, Horng HC, Yu HC, Chen CY. Impact of pregnancy on primary dysmenorrhea. Int J Gynaecol Obstet. 2006;92(3):221–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Barnhart K, Furman I, Devoto L. Attitudes and practice of couples regarding sexual relations during the menses and spotting. Contraception. 1995;51(2):93–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Davis AR, Nowygrod S, Shabsigh R, Westhoff C. The influence of vaginal bleeding on the sexual behavior of urban, Hispanic women and men. Contraception. 2002;65(5):351–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Daley AJ. Exercise and primary dysmenorrhoea: a comprehensive and critical review of the literature. Sports Med. 2008;38(8):659–70.PubMedCrossRefGoogle Scholar
  78. 78.
    Daley AJ. The role of exercise in the treatment of menstrual disorders: the evidence. Br J Gen Pract. 2009;59(561):241–2.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Fisher C, Sibbritt D, Hickman L, Adams JA. Critical review of complementary and alternative medicine use by women with cyclic perimenstrual pain and discomfort: a focus upon prevalence, patterns and applications of use and users’ motivations, information seeking and self-perceived efficacy. Acta Obstet Gynecol Scand. 2016;95:861–71.PubMedCrossRefGoogle Scholar
  80. 80.
    Armour M, Smith CA. Treating primary dysmenorrhoea with acupuncture: a narrative review of the relationship between acupuncture ‘dose’ and menstrual pain outcomes. Acupunct Med. 2016;34(6):416–24.PubMedCrossRefGoogle Scholar
  81. 81.
    Liu CZ, Xie JP, Wang LP, et al. A randomized controlled trial of single point acupuncture in primary dysmenorrhea. Pain Med. 2014;15(6):910–20.PubMedCrossRefGoogle Scholar
  82. 82.
    Smith CA, Armour M, Zhu X, et al. Acupuncture for dysmenorrhoea. Cochrane Database Syst Rev. 2016;(4):CD007854.Google Scholar
  83. 83.
    Wade C, Wang L, Zhao WJ, et al. Acupuncture point injection treatment of primary dysmenorrhoea: a randomised, double blind, controlled study. BMJ Open. 2016;6(1):e008166.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Yang M, Chen X, Bo L, et al. Moxibustion for pain relief in patients with primary dysmenorrhea: a randomized controlled trial. PLoS One. 2017;12(2):e0170952.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Gao J, Wang Q, Xian S, et al. The effect of moxibustion on alleviating menstrual pain in a population of young nursing students: a prospective randomized cross-over pilot study. Complement Ther Med. 2015;23(6):773–81.PubMedCrossRefGoogle Scholar
  86. 86.
    Zhu X, Proctor M, Bensoussan A, et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev. 2007;(2):CD005288.Google Scholar
  87. 87.
    Pan JC, Tsai YT, Lai JN, Fang RC, Yeh CH. The traditional Chinese medicine prescription pattern of patients with primary dysmenorrhea in Taiwan: a large-scale cross sectional survey. J Ethnopharmacol. 2014;152(2):314–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Kokjohn K, Schmid DM, Triano JJ, Brennan PC. The effect of spinal manipulation on pain and prostaglandin levels in women with primary dysmenorrhea. J Manip Physiol Ther. 1992;15(5):279–85.Google Scholar
  89. 89.
    Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2006;(3):CD002119.Google Scholar
  90. 90.
    Hong GY, Shin BC, Park SN, et al. Randomized controlled trial of the efficacy and safety of self-adhesive low-level light therapy in women with primary dysmenorrhea. Int J Gynaecol Obstet. 2016;133(1):37–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Uysal M, Doğru HY, Sapmaz E, et al. Investigating the effect of rose essential oil in patients with primary dysmenorrhea. Complement Ther Clin Pract. 2016;24:45–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Shah M, Monga A, Patel S, Shah M, Bakshi H. The effect of hypnosis on dysmenorrhea. Int J Clin Exp Hypn. 2014;62(2):164–78.PubMedCrossRefGoogle Scholar

Additional Resources

  1. American College of Obstetricians and Gynecologists. Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No. 110. Obstet Gynecol. 2010;115:206–18.CrossRefGoogle Scholar
  2. Anon. Drugs for pain. Treat Guidel Med Lett. 2013;11(128):31–42.Google Scholar
  3. French L. Dysmenorrhea in adolescents: diagnosis and treatment. Paediatr Drugs. 2008;10(1):1–7.PubMedCrossRefGoogle Scholar
  4. Burnett M, Lemyre M. No. 345-primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can. 2017;39(7):585–95.PubMedCrossRefGoogle Scholar
  5. Dawood MY. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs. 1981;22(1):42–56.PubMedCrossRefGoogle Scholar
  6. Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988;84(5A):23–9.PubMedCrossRefGoogle Scholar
  7. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006;108(2):428–41.PubMedCrossRefGoogle Scholar
  8. Drugs for dysmenorrhea. Med Lett Drugs Ther. 1979;21(20):81–4.Google Scholar
  9. Harel Z. Dysmenorrhea in adolescents. Ann N Y Acad Sci. 2008;1135:185–95.PubMedCrossRefGoogle Scholar
  10. Lefebvre G, Pinsonneault O, Antao V, et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can. 2005;27(12):1117–46.PubMedCrossRefGoogle Scholar
  11. Latthe PM, Champaneria R, Khan KS. Dysmenorrhoea. BMJ Clin Evid. 2011;2011. pii: 0813.Google Scholar
  12. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2010;(7):CD001751.Google Scholar
  13. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ Clin Evid. 2007;2007. pii: 0813.Google Scholar
  14. Ryan SA. The treatment of dysmenorrhea. Pediatr Clin N Am. 2017;64(2):331–42.CrossRefGoogle Scholar
  15. Sanfilippo J, Erb T. Evaluation and management of dysmenorrhea in adolescents. Clin Obstet Gynecol. 2008;51(2):257–67.PubMedCrossRefGoogle Scholar
  16. For a quick and general overview of many of the pathologies that cause secondary dysmenorrhea:Google Scholar
  17. Smith RP. Netter’s obstetrics & gynecology. 3rd ed. Philadelphia: Elsevier; 2017. p. 71–3.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Roger P. Smith
    • 1
  1. 1.Florida Atlantic UniversityBoca RatonUSA

Personalised recommendations